Dolutegravir

And you can see there was quite a number of patients.

There were over 6,000 who had switched to a co-formulated Bactegovir FTC tab or a single tablet DTG-based regimen.

So it could be two or three.

And if you look here in the graph, you see that there are three different DTG regimens.

One is the triple therapy with DTG Evacuerate 3TC.

The other is DTG Ropivirine, DTG 3TC, and then there's your BF TAF regimen.

And what they looked at here was something probably many of us don't talk about, but it's proportion of days covered, right? And they broke it down by less than 80% and then greater than or equal to 80%.

And what you see here graphically, there were numerical differences between the two.

So I think it's really a great opportunity to kind of get a sense of what's happening with drug interactions if you want to screen people.

um there's also hiv a table or tab two at the bottom is hiv to hiv drug interaction so many of you may not know this but there's a really great table in dhhs that has specific interactions when you combine two hiv drugs so let's say you're a provider and you want to say you know i'm going to put somebody on dolutegravir but i'm also going to use lenacapavir because it's a treatment experienced patient and that's what you want to do.

So you can actually go into this app and search Dolutegravir and also Lenacapavir.

So it allows these HIV to HIV drug interactions as well, especially like if you're using a non-nuke, for example, with an integration inhibitor or PI with an integration inhibitor, all of those outputs that are in that HIV to HIV drug interaction table and DHHS is actually in this app.

So I think that's really, really helpful.